Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 EV-to-FCF is -16.83 as of Sep. 10, 2026. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 314 Biotechnology companies, SinoMab BioScience ranks worse than 318471.02% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SinoMab BioScience's Enterprise Value is €178.34 Mil.
SinoMab BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.60 Mil. Therefore, SinoMab BioScience's EV-to-FCF for today is -16.83.
The historical rank and industry rank for SinoMab BioScience's EV-to-FCF or its related term are showing as below:
FRA:4VF'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.78 Med: -6.27 Max: -1.65
Current: -17.32
During the past 9 years, the highest EV-to-FCF of SinoMab BioScience was -1.65. The lowest was -22.78. And the median was -6.27.
FRA:4VF's EV-to-FCF is ranked worse than 100% of 314
companies
in the Biotechnology industry
Industry Median: 15.115
vs FRA:4VF: -17.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SinoMab BioScience's PE Ratio (TTM) for today is calculated as:
SinoMab BioScience's share price for today is €0.117.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SinoMab BioScience EV-to-FCF Related Terms
SinoMab BioScience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SinoMab BioScience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's EV-to-FCF falls into.
SinoMab BioScience's current Enterprise Value is €178.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (FRA:4VF) has a EV-to-FCF of -16.83 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #999999 out of 314 companies in the Biotechnology industry.
Is SinoMab BioScience's EV-to-FCF too high?
SinoMab BioScience's current EV-to-FCF is -16.83. Based on the distribution chart, SinoMab BioScience ranks #999999 out of 314 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #999999 out of 314 companies for EV-to-FCF. This places SinoMab BioScience in the lower half of its industry. The industry median EV-to-FCF is 15.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.12, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SinoMab BioScience and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current EV-to-FCF is -16.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current EV-to-FCF of -16.83. The current EV-to-FCF is -16.83. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current EV-to-FCF is -16.83 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
